{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:28:08Z","timestamp":1777404488225,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[1999,5,1]],"date-time":"1999-05-01T00:00:00Z","timestamp":925516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[1999,5]]},"abstract":"<jats:p>Two hundred and fifty patients participated in a 6-month, double-blind study to evaluate safety and e\u00a4cacy of a medium-term treatment with amisulpride 50 mg\/day versus amitriptyline 2575 mg\/day in dysthymia. Patients in treatment groups (165 amisulpride; 85 amitriptyline) were well balanced for demographic and baseline characteristics. A total of 139 patients (93 amisulpride, 46 amitriptyline) completed the study with no statistically signifcant di\u00a1erences in reasons for premature termination between the two groups. A tendency towards a higher incidence of treatment-emergent adverse events with amitriptyline was observed (73% versus 64% amisulpride). In the amitriptyline group, a statistically signifcantly higher incidence of central nervous system (41% versus 24%, p=0.004) and autonomic nervous system disorders (45% versus 16%, p50.0001) was reported. Conversely, endocrine disorders were more frequent with amisulpride (18% versus 7%, p=0.023). E\u00a4cacy was a secondary end-point. Results of the symptom rating scales indicate that both drugs were equally e\u00a1ective: 60% and 62% of patients under amisulpride and amitriptyline, respectively, achieved a reduction 550% of the Montgomery and Asberg Rating Scale total score at end-point. On the item `global improvement' of the Clinical Global Impression, 67% of amisulpride and 68% of amitriptyline patients were rated as `very much' or `much' improved. Results of the present study in a large patient population further confrm the safe use of amisulpride in dysthymia and support its administration upon a medium-term treatment period.<\/jats:p>","DOI":"10.1177\/026988119901300307","type":"journal-article","created":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T23:04:54Z","timestamp":1238627094000},"page":"248-254","source":"Crossref","is-referenced-by-count":28,"title":["Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline"],"prefix":"10.1177","volume":"13","author":[{"given":"L.","family":"Ravizza","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Psychiatric Clinic, University of Torino, Via Cherasco, 11, 10126 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1999,5,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1994.tb05879.x"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02260914"},{"key":"atypb3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2165\/00023210-199504060-00005","volume":"4","author":"Baldwin D","year":"1995","journal-title":"CNS Drugs"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1159\/000026556"},{"key":"atypb5","first-page":"242","volume":"5","author":"Costa, Silva E","year":"1990","journal-title":"Ann Psychiatry"},{"key":"atypb6","first-page":"223","volume-title":"Selective serotonin inhibitors. Advances in basic research and clinical practice","author":"Dunner D L","year":"1996"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n1203"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1016\/0924-9338(96)85186-8"},{"key":"atypb9","first-page":"257","volume":"141","author":"Guelf J D","year":"1983","journal-title":"Am Med Psychol"},{"key":"atypb10","first-page":"217","volume-title":"ECDEU assessment manual for psychopharmacology 1976","author":"Guy W","year":"1976"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"atypb12","first-page":"346","volume":"47","author":"Harrison W","year":"1986","journal-title":"J Clin Psychiatry"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.8.1169"},{"key":"atypb14","first-page":"213","volume":"31","author":"Kocsis J","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1995.tb09580.x"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(96)00103-6"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"atypb18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3565(24)36394-3","volume":"280","author":"Perrault G H","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1177\/070674379403900106"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1984.01790210031005"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(92)90111-Q"},{"key":"atypb22","first-page":"73","volume":"12","author":"Scarzella R","year":"1990","journal-title":"Giornale di Neuropsicofarmacologia"},{"key":"atypb23","volume-title":"The anxiety disease","author":"Sheehan DV","year":"1983"},{"key":"atypb24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","volume":"280","author":"Shoemaker H","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(97)00139-0"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830090023004"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.170.4.345"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(96)88348-9"},{"key":"atypb29","first-page":"2725","volume":"12","author":"Widl\u00cecher D","year":"1980","journal-title":"Psychol Med"},{"key":"atypb30","volume-title":"WHO adverse reactions terminology","author":"World Health Organization","year":"1994"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988119901300307","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988119901300307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T14:06:20Z","timestamp":1740751580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/026988119901300307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,5]]}},"alternative-id":["10.1177\/026988119901300307"],"URL":"https:\/\/doi.org\/10.1177\/026988119901300307","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,5]]}}}